Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

sartan in patients with heart failure and preserved
ejection fraction. N Engl J Med 359:2456, 2008.
353. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin
system inhibitors on mortality and
heart failure hospitalization in patients with heart
failure and preserved ejection fraction: a systematic
review and meta-analysis. J Card Fail 16:260, 2010.
353a. Zile MR, Gaasch WH, Anand IS, et al: Mode of
death in patients with heart failure and a preserved
ejection fraction: results from the Irbesartan in
Heart Failure with Preserved Ejection Fraction
Study (I-Preserve) trial. Circulation 121: 1393,
2010.
354. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan
in a Japanese population with hypertension and
other cardiovascular disease (Jikei Heart Study): a
randomised, open-label, blinded endpoint morbidity-mortality
study. Lancet 369:1431, 2007.
355. Baker WL, Coleman CI, Kluger J, et al. Systematic
review: comparative effectiveness of angiotensinconverting
enzyme inhibitors or angiotensin IIreceptor
blockers for ischemic heart disease. Ann
Intern Med 151:861, 2009.
356. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA,
Weaver WD: Angiotensin converting enzyme inhibitors
in coronary artery disease and preserved
left ventricular systolic function. A systematic review
and meta-analysis of randomized controlled
trials. J Am Coll Cardiol 47: 1576, 2006.
357. Danchin N, Cucherat M, Thuillez C, et al: Angiotensin
converting enzyme inhibitors in patients
with coronary artery disease and absence of heart
failure or left ventricular systolic dysfunction. An
overview of long-term randomized controlled trials.
Arch Intern Med 166: 787, 2006.
358. Dagenais GR, Pogue J, Fox K, et al: Angiotensin
converting enzyme inhibitors in stable vascular
disease without left ventricular systolic dysfunction
or heart failure: a combined analysis of three trials.
Lancet 368: 581, 2006.
359. Solomon SD, Janardhanan R, Verma A, et al: for
the Valsartan in Diastolic Dysfunction (VALIDD)
investigators: Effect of angiotensin receptor blockade
and antihypertensive drugs on diastolic function
in patients with hypertension and diastolic
dysfunction: a randomised trial. Lancet 369: 2079,
2007.
359a. Werner C, Pöss J, Böhm M: Optimal antagonism of
the renin-angiotensin-aldosterone system. Drugs
70: 1215, 2010.
360. Fine EJ. Diuretic renography and angiotensin converting
enzyme inhibitor renography. Radiol Clin
North Am 39:979, 2001.
361. Wu VC, Chang HW, Liu KL, et al. Primary aldo-
References to Chapter 9 9-15
steronism: diagnostic accuracy of the losartan and
captopril tests. Am J Hypertens 22:821, 2009.
362. Rossi GP, Belfiore A, Bernini G, et al. Comparison
of the captopril and the saline infusion test for excluding
aldosterone-producing adenoma. Hypertension
50: 424, 2007.
363. Plata R, Cornejo A, Arratia C, et al: Angiotensinconverting
enzyme inhibition therapy in altitude
polycythaemia: A prospective randomised trial.
Lancet 359:663, 2002.
364. Esposito R, Giammarino A, De Blasio A, et al.
Ramipril in post-renal transplant erythrocytosis. J
Nephrol 20: 57, 2007.
365. Zhu X, Chen J, Han F, et al. Efficacy and safety of
losartan in treatment of hyperuricemia and posttransplantation
erythrocytosis: results of a prospective,
open, randomized, case-control study.
Transplant Proc 41:3736, 2009.
366. Ohtani K, Egashira K, Ihara Y, et al: Angiotensin
II type 1 receptor blockade attenuates in-stent restenosis
by inhibiting inflammation and progenitor
cells. Hypertension 48: 664, 2006.
367. Peters S. Comparison of efficacy of low- (80 mg/
day) and high- (160-320 mg/day) dose valsartan in
the prevention of in-stent restenosis after implantation
of bare-metal stents in type B2/C coronary
artery lesions. Am J Cardiovasc Drugs 8:83, 2008.
368. Gillis AM: Angiotensin receptor blockers for prevention
of atrial fibrillation – a matter of timing or
target? N Engl J Med 360: 1669, 2009.
369. Ehrlich JR, Hohnloser SH, Nattel R: Role of angiotensin
system and effects of its inhibition in atrial
fibrillation: clinical and experimental evidence. Eur
Heart J 27: 512, 2006.
370. Casaclang-Verzosa G, Gersh BJ, Tsang TS: Structural
and functional remodeling of the left atrium:
clinical and therapeutic implications for atrial fibrillation.
J Am Coll Cardiol 51: 1, 2008.
371. Iravanian S, Dudley SC Jr. The renin angiotensin
aldosterone system (RAAS) and cardiac arrhythmias.
Heart Rhythm 5 Suppl: S12, 2008.
372. Jibrini MB, Molnar J, Arora RR: Prevention of atrial
fibrillation by way of abrogation of the renin angiotensin
system: a systematic review and metaanalysis.
Am J Therap 15: 36, 2008.
373. Anand K, Mooss AN, Hee TT, Mohiuddin SM: Meta-analysis:
inhibition of renin-angiotensin system
prevents new onset atrial fibrillation. Am Heart J
152: 217, 2006.
374. Belluzzi F, Sernesi L, Preti P, et al: Prevention of
recurrent lone atrial fibrillation by the angiotensin
II converting enzyme inhibitor ramipril in normotensive
patients. J Am Coll Cardiol 53: 24, 2009.
375. Garg S, Narula J, Marelli C, Cesario D: Role of an-